Etretinate (Tigason) is a vitamin A derivative. The parent vitamin is essential for growth, maintenance of visual function, and the regulation of proliferation and differentiation of epithelial tissues. Because of the effect on the epithelium, vitamin A derivatives have been used in dermatology for the treatment of acne, psoriasis, and other skin conditions.' About 1500 retinoids have been synthesised and biologically tested in the last 15 years.2 Etretinate (an aromatic retinoid) has a therapeutic index 10 times more favourable than the parent all-transretinoic acid in the treatment of skin conditions, and excellent improvements have been achieved with this compound in generalised and refractory pustular forms of psoriasis. 3 Controlled trials of etretinate by dermatologists that demonstrate its efficacy clinically, histologically, and immunologically in psoriatic skin lesions make no mention of a possible action on the joints. In view of the immunosuppressive, immunostimulant, collagenase inhibition, and free oxygen radical inhibition properties of etretinate in animal models it was thought appropriate to conduct a controlled trial of etretinate against ibuprofen (an accepted non-steroidal anti-inflammatory agent) in psoriatic arthritis. Plasma viscosity, C-reactive protein, serum sulphydryl and histidine were added to conventional clinical assessments to confirm the reported effect of the drug on acute phase reactants.
Patients and methods
The patients were between 18 and 70 years, with joint pain involving three or more joints (proximal interphalangeal (PIP) In spite of this we think etretinate was more efficacious than ibuprofen. It is hard to account for the perseverence of the etretinate group to 24 weeks unless their joints were ameliorated more than the ibuprofen group. Significant biochemical improvement occurred over the 24 weeks of etretinate treatment, and we think this unlikely to be spontaneous remission alone, since biochemical improvement was seen in the ibuprofen 'nonresponders' who elected to transfer to etretinate. Thus for those patients whose biochemical parameters remained unaltered during eight or 12 weeks of ibuprofen therapy, a fall in CRP from a mean of 1*56 to 0*67, and a rise in histidine from a mean of 1-31 to 1*40 was seen during the first 12 weeks of therapy.
Our results provide modest confirmation of earlier uncontrolled reports that etretinate is effective in psoriatic arthritis. These earlier results do not enable one to ascertain whether these patients elected to remain on the drug because of improvement in the skin. Certainly we have confirmed the biochemical improvement in disease activity that has previously been reported with this drug6 7 and think this is unlikely to be explicable entirely in terms of spontaneous remission. It remains a possibility that we evaluated the drug at too low a dose, though we feel the frequency of side effects seen would have militated against its use at a higher dose in this condition.
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